Clinical trial NCT02536742: Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Official title: A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Breast Cancer
Keywords: Breast Cancer
Metastatic
HER2 negative
Palbociclib
Lead sponsor: ETOP IBCSG Partners Foundation
Sponsor class: NETWORK
Collaborators: name: Breast International Group
First posted: 2015-09-01
Enrollment: 124
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This international, multicenter, prospective single arm Phase II biomarker discovery clinical trial with the primary objective of assessing the association of PFS with gene mutations, gene copy number aberrations and gene signatures in post-menopausal women with hormone receptor positive, HER2-negative metastatic or locally relapsed breast cancer whose disease has progressed after prior adjuvant endocrine therapy or one line systemic treatment, i.e., endocrine treatment or chemotherapy, administered for metastatic disease.

Detailed description: Patients will be treated with the combination of palbociclib and fulvestrant. The primary objective is to assess the association of the primary endpoint progression-free survival (PFS) with potential markers.

The trial is included in the AURORA program conducted by the Breast International Group (BIG), an international study aiming to collect and characterize biological samples, including metastatic tissue, from patients with advanced breast cancer.

The primary aim of the PYTHIA study is to discover potentially innovative biomarkers for the selection of patients to Palbociclib/Fulvestrant treatment. The strength of the trial lies in its conduct in conjunction with the AURORA study, which systematically evaluates a panel of biomarkers in tissue and blood, in a certified central lab. Stemming from this association, an abundance of molecular profiling information will become available for different biological samples. Additional molecular and functional imaging assessments performed within the context of the PYTHIA study increase its scientific merit, since it will represent a prospective, systematic effort to identify biomarkers for patient stratification, integrating several molecular profiling assessments.

Eligibility criteria: Inclusion Criteria:

* Female gender
* Age ≥ 18 years
* Postmenopausal, defined as women with:

  * Prior bilateral surgical oophorectomy; or
  * Amenorrhea and age ≥ 60 years; or
  * Age \< 60 years and amenorrhea for 12 or more consecutive months in the absence of alternative pathological or physiological cause and FSH and serum estradiol levels within the laboratory's reference ranges for postmenopausal women.
* Endocrine resistant disease, defined as one of:

  * Relapse while on adjuvant endocrine therapy;
  * Relapse within 12 months after completion of adjuvant endocrine therapy;
  * Progression of disease under first line endocrine therapy for metastatic and/or loco-regionally advanced breast cancer.

Note: Patient may have received one prior chemotherapy for advanced or metastatic breast cancer.

* ER positive tumor and HER2-negative tumor, as assessed locally
* ECOG Performance Status 0-1.
* Measurable or non-measurable but evaluable disease according to RECIST 1.1.
* Written Informed Consent (IC) for screening procedures.
* Written informed consent to participate in the AURORA program of BIG.
* The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
* Life expectancy \>3 months.
* Hematological status:

  * Absolute neutrophil count ≥ 1.5 × 109/L
  * Platelet count ≥ 100 × 109/L
  * Hemoglobin ≥ 9 g/dL
* Hepatic status:

  * Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN).
  * AST and ALT ≤ 2.5 × ULN; if the patient has liver metastases, ALT and AST must be ≤ 5 × ULN.
* Glucose in normal range, or well-controlled diabetes defined as an HbA1c level ≤ 7.5%.
* Renal status:

  - Creatinine ≤ 1.5 ×ULN or creatinine clearance \> 60 ml/min.
* International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant.
* Ability to swallow oral medication.

Exclusion Criteria:

* Prior use of fulvestrant or any CDK inhibitor.
* More than one prior line of chemotherapy for metastatic or locally relapsed disease.
* Previous or current non-breast malignancies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
* Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.
* Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA functional classification ≥3), cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
* QTc exceeding 480msec, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).
* Uncontrolled electrolyte disorders that can reinforce the QT-prolonging effect of the drug (e.g., hypocalcemia, hypokalemia, hypomag¬nesemia).
* Known history of HIV seropositivity. HIV screening is not required at baseline.
* Uncontrolled diabetes defined as HbA1c level \> 7.5%.
* Concurrent disease or familial, sociological or geographical condition that would make the patient inappropriate for trial participation or any serious medical disorder that would interfere with the patient's safety.
* Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of Informed Consent.
* Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant.
* Treatment with an investigational agent in the 4 weeks before enrollment.
* Concurrent treatment with any of the drugs not permitted
* Adverse events (except alopecia) from previous systemic cancer therapy, radiotherapy or surgery have not recovered to CTCAE v4.0 grade 1 or resolved prior to enrollment.

Primary outcomes:
measure: Number of Participants With and Without Progression Free Survival (PFS) Events
timeFrame: Maximum 36 months
Secondary outcomes:
measure: Best Overall Response
timeFrame: From date of enrolment until patient's end of treatment visit (or a maximum of 12 months after EoT in the absence of tumor progression), assessed up to 48 months.
measure: Best Overall Response of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD)
timeFrame: From date of enrolment until patient's end of treatment visit (or a maximum of 12 months after EoT in the absence of tumor progression), assessed up to 48 months.
Other outcomes:
Locations:
city: Antwerpen
country: Belgium
facility: Sint-Augustinus
city: Brussels
country: Belgium
facility: Institut Jules Bodet
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc
city: Edegem
country: Belgium
facility: Antwerp University Hospital
city: Leuven
country: Belgium
facility: UZ Leuven
city: Liège
country: Belgium
facility: CHU Liege
city: Namur
country: Belgium
facility: Clinique St. Elizabeth
city: Biella
country: Italy
facility: Ospedali degli Infermi, S.O.C. Oncologia
city: Bolzano
country: Italy
facility: Ospedale Centrale Bolzano, Medical Oncology
city: Genova
country: Italy
facility: IRCCS San Martino University Hospital
city: Legnago
country: Italy
facility: Mater Salutis Hospital AULSS 21 della Regione Veneto
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia
city: Pavia
country: Italy
facility: Istituti Clinici Scientifici Maugeri, Medical Oncology Unit
city: Prato
country: Italy
facility: Azienda USL4 Prato
city: Cardiff
country: United Kingdom
facility: Velindre NHS Trust
city: Edinburgh
country: United Kingdom
facility: Western General Hospital
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: Swansea
country: United Kingdom
facility: Singleton Hospital
city: Truro
country: United Kingdom
facility: Royal Cornwall
Study officials:
affiliation: USL4 Hospital of Prato, Italy
name: Luca Malorni, MD PhD
role: STUDY_CHAIR
References:
citation: Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10.
citation: Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.
citation: Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.
citation: Di Leo A, Malorni L. Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. J Clin Oncol. 2012 Jun 1;30(16):1897-900. doi: 10.1200/JCO.2012.41.7394. Epub 2012 Apr 30. No abstract available.
citation: Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM; International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022 Mar;164:39-51. doi: 10.1016/j.ejca.2021.12.030. Epub 2022 Feb 13.